Ribociclib in 1st line HR+ breast cancer treatment

Cover Page

Cite item

Full Text

Abstract

Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.

About the authors

L G Zhukova

A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow

Email: zhukova.lyudmila@rambler.ru
д-р мед. наук, зам. директора по онкологии 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86

I P Ganshina

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

канд. мед. наук, вед. науч. сотр. отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

O O Gordeeva

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

клинический аспирант отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E V Lubennikova

N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

врач-онколог отд-ния химиотерапии и комбинированного лечения злокачественных опухолей 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
  2. Anderson W.F et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002; 76: 27-36.
  3. Ignatov A et al. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol 2018 Apr 19.
  4. Beaver J.A et al. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651-7.
  5. Di Leo A et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19 (1): 87-100.
  6. Finn R. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25-35.
  7. Hanahan D, Weinberg R.A. The hallmarks of cancer. Cell 2000; 100: 57-70.
  8. Hanahan D, Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74.
  9. Kollmann K. et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013; 24: 167-81.
  10. Casimiro M.C. et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013; 27: 1415-28.
  11. Hortobagyi G. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-48.
  12. Hortobagyi G. et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). J Clin Oncol 2017; 35 (15 Suppl.): 1038.
  13. Tripathy D. et al. 2017 San Antonio Breast Cancer Symposium. December 5-9, 2017. Abstract GS2-05.
  14. Fasching P. et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol 2016; 34 (15 Suppl.).
  15. https://clinicaltrials.gov/ct2/show/NCT02941926

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).